Literature DB >> 8161354

Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver.

C M Dixon1, G R Park, M H Tarbit.   

Abstract

Studies have been undertaken to investigate the enzymes responsible for the metabolism of [14C]sumatriptan in man. Oxidative deamination of sumatriptan to form the indole acetic acid derivative is the only phase 1 pathway evident in man and both cytochrome P450 (P450) and monoamine oxidase (MAO) are capable of catalysing this type of reaction. The metabolism of [14C]sumatriptan was therefore investigated in vitro in a preparation derived from human liver, which was shown, by the use of the probe substrates [14C]testosterone (P450), [3H]5HT (MAO-A) and [14C]benzylamine (MAO-B) to be a rich source of both enzyme systems. Incubation with clorgyline and deprenyl, probe inhibitors of MAO-A and MAO-B, respectively, showed that [14C]sumatriptan was metabolized by MAO-A; there was no evidence of P450 involvement in its metabolism. The data in this study therefore indicate that the enzyme MAO-A is the major enzyme responsible for the metabolism of sumatriptan in human liver.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8161354     DOI: 10.1016/0006-2952(94)90397-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  15 in total

Review 1.  Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review.

Authors:  S S Jhee; T Shiovitz; A W Crawford; N R Cutler
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 2.  Molecular basis of polymorphic drug metabolism.

Authors:  A K Daly
Journal:  J Mol Med (Berl)       Date:  1995-11       Impact factor: 4.599

Review 3.  The role of non-P450 enzymes in drug oxidation.

Authors:  C Beedham
Journal:  Pharm World Sci       Date:  1997-12

4.  Utilization of Liver Microsomes to Estimate Hepatic Intrinsic Clearance of Monoamine Oxidase Substrate Drugs in Humans.

Authors:  Yusuke Masuo; Shushi Nagamori; Aoi Hasegawa; Kazuki Hayashi; Noriyoshi Isozumi; Noritaka Nakamichi; Yoshikatsu Kanai; Yukio Kato
Journal:  Pharm Res       Date:  2017-03-30       Impact factor: 4.200

5.  Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol.

Authors:  M R Goldberg; D Sciberras; M De Smet; R Lowry; L Tomasko; Y Lee; T V Olah; J Zhao; K P Vyas; R Halpin; P H Kari; I James
Journal:  Br J Clin Pharmacol       Date:  2001-07       Impact factor: 4.335

6.  Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans.

Authors:  J C Fleishaker; K K Ryan; J M Jansat; B J Carel; D J Bell; M T Burke; N E Azie
Journal:  Br J Clin Pharmacol       Date:  2001-05       Impact factor: 4.335

Review 7.  Indolealkylamines: biotransformations and potential drug-drug interactions.

Authors:  Ai-Ming Yu
Journal:  AAPS J       Date:  2008-05-03       Impact factor: 4.009

8.  An in vitro interethnic comparison of monoamine oxidase activities between Japanese and Caucasian livers using rizatriptan, a serotonin receptor 1B/1D agonist, as a model drug.

Authors:  T Iwasa; H Sano; A Sugiura; N Uchiyama; K Hara; H Okochi; K Nakagawa; T Yasumori; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  2003-11       Impact factor: 4.335

Review 9.  Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal.

Authors:  Chaouki K Khoury; James R Couch
Journal:  Drug Des Devel Ther       Date:  2010-02-18       Impact factor: 4.162

10.  Sumatriptan absorption from different regions of the human gastrointestinal tract.

Authors:  P E Warner; K L Brouwer; E K Hussey; G E Dukes; W D Heizer; K H Donn; I M Davis; J R Powell
Journal:  Pharm Res       Date:  1995-01       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.